1. Home
  2. Product Information
  3. 5-HT2B Antagonist

Product Information

5-HT2B Antagonist

Compound Code RQ-00310941
Primary Target Indications Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)
Development Stage Phase 1 (UK)
Portfolio for global development, manufacturing, and marketing rights
Product Summary 5-HT2B receptors are widely distributed through-out the human intestinal tract and are thought to be a viable new target for irritable bowel syndrome (IBS) treatment. This compound, a 5-HT2B antagonist with high activity and selectivity, has proven to be effective for suppression of visceral hypersensitivity and abnormal defecation in animal models of IBS, without affecting normal defecation. It has the potential to be an effective drug for IBS and other functional gastrointestinal disorders. The needs for effective drugs for functional gastrointestinal disorders have been increasing not only in Japan but also all over the world, and the 5-HT2B antagonist is expected to open and grow a new market in this field.

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics